Boukhaled, Giselle M. http://orcid.org/0000-0002-6567-6234
Gadalla, Ramy
Elsaesser, Heidi J.
Abd-Rabbo, Diala
Quevedo, Rene
Yang, S. Y. Cindy
Guo, Mengdi
Wang, Ben X.
Noamani, Babak
Gray, Diana
Lau, Sally C. M.
Taylor, Kirsty
Aung, Kyaw
Spreafico, Anna
Hansen, Aaron R.
Saibil, Samuel D.
Hirano, Naoto http://orcid.org/0000-0001-9070-4754
Guidos, Cynthia http://orcid.org/0000-0002-7674-2612
Pugh, Trevor J.
McGaha, Tracy L.
Ohashi, Pamela S.
Sacher, Adrian G.
Butler, Marcus O. http://orcid.org/0000-0002-9840-7057
Brooks, David G. http://orcid.org/0000-0001-7763-8764
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI08504)
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (FDN148386)
Canadian Cancer Society Research Institute (706230)
Article History
Received: 19 July 2021
Accepted: 9 June 2022
First Online: 14 July 2022
Competing interests
: A.R.H. provides consultation/advice for Merck, GlaxoSmithKline, Bristol-Myers Squibb and Eisai, and receives research funding for Karyopharm Therapeutics, Merck, GlaxoSmithKline, Bristol-Myers Squibb, Roche/Genentech, Boeringher Ingelheim, Janssen, AstraZeneca/MedImmune, Astellas and Macrogenics. A.S. is a consultant for (Advisory Board): Merck (compensated), Bristol-Myers Squibb (compensated), Novartis (compensated), Oncorus (compensated) and Janssen (compensated). A.S. receives grant/research support from (Clinical Trials): Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, Treadwell. P.S.O. is a scientific advisory board member for Providence, Tessa and holds a sponsored research agreement with EMD Serono. M.O.B. is a consultant and on the advisory board for: Merck, Bristol-Myers Quibb, Novartis, GlaxoSmithKline, Sanofi, LaRoche, Possey, Sun Pharma, Instil Bio, IOVANCE and Pfizer, and receives grant funding from Merck, Takara and the safety review committee for Adaptimmune. G.M.B., H.J.E. and D.G.B. have filed a provisional patent pertaining to this work. The remaining authors declare no competing interests.